Business

Earth Science Tech Enters Negotiations for MSN-2 and Nanoderm Distribution in Three Countries and Plans New Clinical Study with HIV-Seropositive and AIDS Patients

Earth Science Tech Enters Negotiations for MSN-2 and Nanoderm Distribution in Three Countries and Plans New Clinical Study with HIV-Seropositive and AIDS Patients.

articleEarth Science Tech, Inc.November 30, 20173/company/earth-science-tech-inc/news/earth-science-tech-enters-negotiations-for-msn-2-and-nanoderm-distribution-in-three-countries-and-plans-new-clinical-study-with-hiv-seropositive-and-aids-patients
Earth Science Tech Enters Negotiations for MSN-2 and Nanoderm Distribution in Three Countries and Plans New Clinical Study with HIV-Seropositive and AIDS Patients

About this update from Earth Science Tech, Inc.

[{"type":"text","content":"\n\n Doral, FL, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) (\"ETST\" or \"the Company\"), an innovative biotech company that operates in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical, medical device, research and development, is negotiating on medical device promotion options, and plans to launch a clinical study with HIV-seropositive and AIDS patients in the near future.\n As previously announced, ETST will initiate the distribution of its medical devices in Djibouti and Morocco (http://www.otcmarkets.com/stock/ETST/news/Earth-Science-Tech--Inc--Announces-New-Agreement-with-Axcelon-Biopolymers-Corp--for-Distribution-of-Nanoderm-trade--Medical-Device--amp--Advances-with-Its-MSN-2-Medical-Device?id=170151&b=y ). As the company waits for regulatory clearance to launch in North America, the company will have already collected valuable sales data from international markets. ETST is also developing an imminent partnership agreement to reach the Vietnamese market for the MSN-2 medical device. Additionally, original branding and graphical elements will be coming in soon (http://www.otcmarkets.com/stock/ETST/news/Earth-Science-Tech--Inc--Signs-Contract-with-Absolu-to-Advance-Phase-2-Rollout-on-MSN-2-Medical-Device?id=166272&b=y), and the Nanoderm™ medical device which was developed by a member of the ETST advisory board, Dr. Chandra Panchal (Founder, Chairman, Chief Executive Officer and Chief Scientific Officer of Axcelon Biopolymer: http://axcelonbp.com/companay/board-of-directors/ ). Only some details remain to be discussed and the new Vietnamese market partner will be announced before year end. The company is also in discussions to introduce its high-grade CBD hemp oil in the primary launch countries. The first samples of MSN-2 and Nanoderm™ are being sent to Djibouti, Morocco, and Vietnam, in order to start negotiations with local authorities and partners alike. In Vietnam the products will be presented directly to hospital administrators and physicians by ETST’s new American partner who is of Vietnamese origin. This forthcoming partner has been a distributor of medical devices for many years, and saw a huge opportunity working with Earth Science Tech in its early growth phases. New clinical study of HIV seropositive and AIDS-infected patients ETST is ...

More updates from Earth Science Tech, Inc.